US pharmaceutical company Moderna Inc (Nasdaq:MRNA) is in talks with US regulators to expand the size of an ongoing trial testing its COVID-19 vaccines in children aged between five and 11, Reuters news agency reported on Tuesday.
Moderna stated that the objective of the discussion with the US Food and Drug Administration is to enrol a larger safety database, which increases the likelihood of detecting rarer events.
The country expects to have a package that supports authorisation in winter of 2021 or early 2022, a company spokesperson told Reuters.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT